The following link shows our products.
http://www.genoprice.com/BioCurexBro...
SERUM ASSAYS TO DETECT RECAF™ (THE RECEPTOR FOR ALPHA-FETOPROTEIN) IN SERUM
FORMATS: ELISA (450 nm), flash Chemiluminescense Immunoassay (CIA)
and
125
I Radioimmunoassay (RIA).
RECAF™ is a novel biochemical marker which is
expressed in the cells of cancer patients.
PRODUCT FEATURES
Catalog Numbers: CIA-92001, RIA 92001
96 Well Microplate Format
Detection System: CIA or RIA
Individual Strips/Wells: Yes
High Sensitivity: 80-90%
High Speci!city: 95%
Rapid Assay Time: 3 hours
Sample Type: Serum
Sample Size: 5 microliters
Sample Size: < 50 microliters
Applicable to Multiple Cancer Types:
Ovarian, Prostate, Breast, Stomach,
Pancreas, Lymphomas, Cervical, LungLung
Available for research use only/investigational use only.
Reagents available for AnalyteSpeci!c Reagent (ASR) in
the United States and Canada.
Cancer type
Sensitivity with 95%
Specificity
Sensitivity with 99%
Specificity Number
Ovarian Ca 96% 92% 162
Stomach Ca 90% 87% 31
Lung Ca 91% 87% 32
Breast Ca 93% 90% 88
Prostate Ca vs. Normal 99% 95% 20
TOTAL 94% 91% 333
Breast Benign* 0 0 22
Prostate Benign* 25% 5% 77
*At the 95% cutoff value, a small percentage of benign breast and prostate samples were positive. Increasing the cut-off value to include
99% of normal individuals reduces the percentage of false positives, at the expense of a slight decrease in sensitivity
BioCurex, Inc
215-7080 River Road
Richmond, BC V6X 1X5
Canada
Phone: (604) 207-9150
Fax: (604) 207-9165
Email:
info@biocurex.com
Website:
www.biocurex.com
Distributed By:
BioCurex, Inc
215-7080 River Road
Richmond, BC V6X 1X5
Canada
BioCurex, Inc
215-7080 River Road
Richmond, BC V6X 1X5
Canada
Phone: (604) 207-9150
Fax: (604) 207-9165
Email:
info@biocurex.com
Website:
www.biocurex.com
Distributed By:
SERUM ASSAYS TO DETECT RECAF™ (THE RECEPTOR FOR ALPHA-FETOPROTEIN) IN SERUM
In a study comparing normal patients, patients with BPH (Benign Prostate Hyperplasia) and
patients with prostate cancer:
1) RECAF™ detected early stage prostate cancer
2) RECAF™ discriminated prostate cancer from BPH substantially better than total-PSA
(tPSA) or free-PSA (fPSA)
3) RECAF™ discriminated between BPH and prostate cancer significantly better than
thethe generally accepted discrimination obtainable with tPSA or fPSA using tPSA or
Cancer Stage SENSITIVITY SPECIFICITY NUMBER OF SAMPLES
Stage I 90% 100% 42
Stage II 93% 100% 45
In a blinded study RECAF™ has been shown to detect early stage breast cancers. Data collected on
Stage I and Stage II cancers are shown below.
#Typical data obtained with a Radioimmunoassay (RIA).
